SCHEMBL5577485

SCHEMBL5577485

COC(=O)N(Cc1ccccc1)c1ccccc1C1CCN(Cc2ccc(F)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
SIGMAR1 Q99720 3/20 0.50
GAA P10253 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
ACHE P22303 2/20 0.48
BCHE P06276 1/20 0.48
BACE1 P56817 1/20 0.48
SLC6A12 P48065 1/20 0.47
TMEM97 Q5BJF2 1/20 0.47
MCHR1 Q99705 1/20 0.47
CHRM4 P08173 3/20 0.47
UBE2M P61081 1/20 0.45
DCUN1D1 Q96GG9 1/20 0.45
OPRM1 P35372 1/20 0.45
CACNA1G O43497 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5577753 0.90 ACHE (0.46) MEN1KMT2ASIGMAR1GAAKDM4E
SCHEMBL5577529 0.89 MEN1 (0.48) MEN1KMT2ASIGMAR1GAAKDM4E
SCHEMBL5577411 0.87 GAA (0.47) MEN1KMT2ASIGMAR1GAAKDM4E
SCHEMBL5577802 0.87 DRD3 (0.49) MEN1KMT2ASIGMAR1GAAKDM4E
SCHEMBL5577780 0.85 MEN1 (0.51) MEN1KMT2ASIGMAR1CHRM4
SCHEMBL5577698 0.85 MEN1 (0.48) MEN1KMT2ASIGMAR1GAAKDM4E
SCHEMBL5577273 0.85 SIGMAR1 (0.45) MEN1KMT2ASIGMAR1GAAKDM4E
SCHEMBL5577483 0.83 ACHE (0.49) MEN1KMT2ASIGMAR1GAAKDM4E
SCHEMBL5577606 0.83 GAA (0.54) MEN1KMT2ASIGMAR1GAAKDM4E
SCHEMBL5577533 0.79 GAA (0.59) MEN1KMT2ASIGMAR1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-22 US disclosed
EP-1616862-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof HLA-DRB1, MIF, HLA-C MEN1 748/4885KMT2A 3527/4885SIGMAR1 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.